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ABSTRACT
Objectives: To test whether administration of the antifibrinolytic drug tranexamic acid
(TXA) in patients with spontaneous intracerebral haemorrhage (SICH) leads to
increased prevalence of diffusion-weighted MRI defined hyperintense ischaemic
lesions (primary hypothesis) or reduced perihaematomal oedema volume,
perihaematomal diffusion restriction and residual MRI-defined SICH-related tissue
damage (secondary hypotheses).
Design: MRI sub-study nested within the double-blind randomised controlled TICH-
2 trial (ISRCTN93732214).
Setting: International multi-centre hospital-based study.
Participants: Eligible adults consented and randomised in the TICH-2 trial who were
also able to undergo MRI scanning. To address the primary hypothesis a sample size
of n=280 will allow detection of a 10% relative increase in prevalence of diffusion
weighted imaging hyperintense lesions in the TXA group with 5% significance, 80%
power and 5% imaging data rejection.
Interventions: TICH-2 MRI sub-study participants will undergo MRI scanning using
a standardised protocol at day ~5 and day ~90 after randomisation. Clinical
assessments, randomisation to TXA or placebo and participant follow-up will be
performed as per the TICH-2 trial protocol.
Conclusion: The TICH-2 MRI sub-study will test whether TXA increases the
incidence of new DWI-defined ischemic lesions or reduces perihaematomal oedema
or final ICH lesion volume in the context of SICH.
STRENGTHS AND LIMITATIONS
 Magnetic resonance imaging (MRI) is incorporated into an international multi-
centre randomised controlled trial of tranexamic acid (TXA) in spontaneous
intracerebral haemorrhage (SICH). This will be used to objectively assess the
potential effects of TXA on cerebral ischemia, which might not be visible using
standard clinical imaging such as computed tomography.
 This study also uses MRI to assess any potential beneficial effects of TXA on
neurotoxicity and neuroinflammation.
 The inclusion of MRI necessitates the introduction of additional exclusion
criteria, which increases the risk of under-recruitment and subsequent reduction
of statistical power.
 A limitation of the recruitment process to the TICH-2 MRI sub-study is that
recruitment took place after-randomisation. As a result survivor bias may be a
potential confounder, which we address by conducting regression analyses
adjusting for baseline variables.
INTRODUCTION AND RATIONALE
Tranexamic acid (TXA) is an antifibrinolytic drug that binds reversibly to the lysine
binding site of plasminogen / plasmin [1], leading to potent inhibition of the interaction
of plasmin with fibrin that results in reduced fibrinolysis. In the context of spontaneous
intracerebral haemorrhage (SICH) it has been postulated that TXA will result in more
rapid cessation of bleeding at the point of vessel rupture and hence limit haematoma
expansion, a factor shown to be associated with both mortality and disability [2]. The
Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage (TICH-2) trial is
an international multi-centre randomised controlled trial to test the hypothesis that
intravenous TXA reduces death and disability when given within 8 hours of SICH
(ISRCTN93732214) [3]. However, there are alternative mechanisms in addition to
haemostatic by which TXA, could alter the pathophysiology, and hence outcome, of
the evolving brain injury that accompanies SICH via its interaction with the
plasminogen activation axis.
Firstly, patients with SICH are at risk of co-occurring cerebral ischaemic events, and
TXA could theoretically potentiate this risk by the inhibition of fibrin degradation.
Diffusion weighted imaging (DWI) MRI hyperintense lesions (DWIHL), which are
thought to be indicative of acute or subacute ischaemia, co-occur with SICH with a
prevalence (8-35%) [4–7] and are associated with a higher risk of dependence or
death at 3 months (OR 4.8; 95% CI 1.7–13.9; P=0.004) [8]. The mechanisms
underlying the high prevalence of DWIHL in SICH are not known. Endothelial failure
is thought to be a key event in the mechanism of small vessel disease and lacunar
infarction [9]. A sequential process of endothelial failure, non-occlusive wall-
associated microthrombosis, vessel rupture, microbleeding, and finally reactive
occlusive thrombosis leading to infarction has been proposed based on animal models
[10]. The inhibition of fibrin degradation by TXA could potentiate this process by
exacerbation of microvascular thrombosis. Support for a possible potentiating effect
of TXA on cerebral ischaemia comes from a meta-analysis of predominantly prolonged
(>10 days) TXA administration in spontaneous subarachnoid haemorrhage (SAH)
which found pooled relative risk for reported cerebral ischaemia of 1.41 (95% CI 1.04-
1.91) [11]. However multiple studies of TXA in a variety of other disease settings,
including traumatic and spontaneous bleeding (non-SAH) showed no increase in
cerebral ischaemia with TXA use [12–15].
Secondly, there are potentially beneficial effects of TXA by modulation of the
plasminogen activation cascade by reducing neurotoxicity and neuroinflammation
[16–18]. A study in surgical patients has shown that TXA attenuates the inflammatory
response [19], thought to be mediated by inhibition of the plasminogen activation
cascade. Clinical and biological markers of inflammatory response at presentation are
predictors of early neurological deterioration in SICH [20]. Perihaematomal oedema
(PHO) volume and diffusion properties have been proposed as biomarkers of the
inflammatory response around SICH [21], and levels of circulating matrix
metalloproteinase-3 are independently associated with PHO volume [22]. PHO
increases rapidly during the first 48 hours and peaks towards the end of the second
week following SICH [23]. MRI DWI of PHO most commonly shows elevated diffusion
[24,25] implying that PHO results from increased permeability of the neurovascular
unit or alterations in the extravascular ultrastructural environment rather than
ischaemia, although in cases where restricted diffusion is detected in PHO an
association with poor clinical outcome has been observed [26].
In the TICH-2 MRI sub-study MRI scans will be acquired in a sub-group of the TICH-
2 Trial population on day 5 after randomisation (acceptable range day 2 to day 14,
referred to hereafter as the day 5 scan), and day 90 after randomisation (acceptable
range day 83 to day 110, referred to as the day 90 scan). The MRI data will be used
to test a primary hypothesis regarding treatment-related differences in DWIHL
prevalence. It will also allow secondary analyses of treatment effects on PHO volume
and diffusion properties, and SICH-related tissue damage at day 90.
Primary hypothesis
Prevalence of remote DWI hyperintense lesions on the day 5 MRI scan will be greater
in the TXA group compared to controls.
Secondary hypotheses
1) Perihaematomal oedema volume and perihaematomal diffusion restriction on
day 5 MRI scan will be reduced in the TXA group compared to controls.
2) SICH-related tissue damage defined on the day 90 MRI scan will be reduced in
the TXA group compared to controls, controlling for initial haematoma volume.
We will test whether imaging markers of co-existing small vessel disease (cerebral
microbleeds, CMB, and white matter hyperintensities of presumed vascular origin,
WMH) and imaging markers of cerebral amyloid angiopathy (CAA; strictly lobar CMB,
cortical superficial siderosis) are associated with the presence of DWIHL in TXA
treated patients.
DESIGN AND METHODS
Patient population
The recruitment process is summarised in Figure 1. Patients recruited to the main
TICH-2 trial according to the TICH-2 trial inclusion and exclusion criteria [3] (see
supplementary information) at centres participating in the TICH-2 MRI sub-study will
be invited to participate in the TICH-2 MRI sub-study provided they meet the additional
following inclusion / exclusion criteria:
 Additional TICH-2 MRI study inclusion criteria:
1. Participant or delegate freely gives informed consent to participate in the TICH-
2 MRI sub-study, or participants within the TICH-2 Trial who have an MRI scan
performed for clinical purposes within the MRI sub-study time windows using a
protocol consistent with the MRI sub-study (TICH-2 trial consent includes
submission of relevant clinical data which includes imaging data).
2. Able to undergo MRI scanning.
 Additional TICH-2 MRI sub-study exclusion criteria:
1. Contraindication to MRI scan (e.g., non-MRI compatible implant, intra-ocular /
intracranial metallic device or fragment, claustrophobia, etc.).
2. Clinical instability (for example cardiorespiratory or neurological instability) such
that MRI scan would introduce additional clinical risk.
Randomisation
Participants are randomised into the main TICH-2 study as described previously [3].
Recruitment into the TICH-2 MRI sub-study can occur at any time between the point
of initial recruitment to the main TICH-2 study (pre-randomisation) up to day 7 after
randomisation. Blinding to treatment allocation is maintained throughout the course of
both the TICH-2 main and MRI sub-study.
Intervention
The TICH-2 trial intervention has been described previously [3]. In brief, participants
are randomised (1:1) to intravenous tranexamic acid (1g in 100ml IV bolus loading
dose followed by 1g in 250ml infusion over 8 hours) or placebo (0.9 % saline using
identical administration regime).
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Table 1 - MRI acquisition parameters. Preferred parameters are listed, with acceptable
range of values given in brackets for sites where the preferred parameters cannot be
achieved for technical reasons.
MRI scanning is performed on day 5 (acceptable range day 2 to day 14) and day 90
(acceptable range day 83 to day 110) post-randomisation. The MRI acquisition
protocol (Table 1) complies with the essential imaging sequences specified by the
Standards for Reporting Vascular Neuroimaging (STRIVE) standards [9], and includes
2D axial, T2-weighted images, T2*-weighted images, T2-weighted Fluid-attenuated
inversion recovery (FLAIR) images, DWI, and a 3D T1-weighted volume acquisition.
Axial 2D T1-weighted images are to be included if the 3D T1-weighted volume is
significantly motion degraded, and manufacturer optimised susceptibility weighted
imaging (SWI) is to be included if available.
Outcomes
Primary outcome
 Prevalence of remote DWIHL on the day 5 MRI scan
Secondary outcomes
 Perihaematomal oedema volume and perihaematomal diffusion restriction on
the day 5 MRI scan
 SICH-related tissue damage (the combined volume of the residual haematoma
cavity and surrounding FLAIR hyperintensity) determined on the day 90 MRI
scan.
Methodology for extraction of the imaging outcome measures is summarised in Figure
2. DWI scans will be analysed for presence, number and distribution of DWIHL. A
semi-automated method for quantification of DWIHL will be developed and validated
using a subset of patients. It will be subsequently employed to identify candidate
lesions based on shape and intensity features. Candidate lesions will then be accepted
or rejected by at least two expert readers independently. Only DWIHL that are
confirmed of low diffusion on the derived apparent diffusion coefficient maps, and
spatially remote from the index ICH (<20mm) will be included as previously [6].
A fully automated segmentation method [27] will exploit the T2, T2* and FLAIR images
to segment the haematoma and PHO on the day 5 MRI scan (limited for secondary
hypothesis 1 to scans performed up to and including day 7), from which volume and
quantification of the diffusion properties of PHO can be derived (Figure 3). FLAIR
images will be used to determine the volume of final haematoma cavity and
surrounding hyperintensity on the day 90 scan using semi-automated segmentation
supervised by experienced image analysts. T1-weighted images will be utilised to
determine brain parenchymal volume on the day 90 scan.
WMH will be evaluated on FLAIR and T2-weighted images using an established 4
point scale [28] and automated WMH segmentation will be used for WMH volume
calculation and creation of a distribution map of WMH. CMB number and distribution
will be rated using Microbleed Anatomical Rating Scale (MARS) and used for
classification of ICH patients into probable CAA and non-CAA groups [29].
Sample size estimates
Primary hypothesis: Based on previous studies finding prevalence of DWIHL of 20%
in SICH, we performed calculations for sample size to allow us to detect different
percentage increases in DWIHL prevalence in the TXA group above a 20% baseline,
using the sample size formula for prevalence:
݊= (ݖଵିఈ ଶൗଶ ) ∙ ݌(1 − ݌)
݉ ଶ
, (1)
where z = confidence interval, p = prevalence, and m = margin of error (standard is
5%). Assuming a 10% relative increase in prevalence of DWIHL (i.e. from 20% to
22%) in the TXA group, with 5% significance and 80% power, a sample size of 264 is
required. Allowing 5% imaging data rejection (e.g. due to excessive patient motion),
a sample size of 280 is required.
Secondary hypotheses: Our pilot data from the TICH-1 study [30] showed that for
every 1ml of SICH volume, the mean relative PHO volume increased between the Day
0 and Day 2 CT scan by 0.29ml (standard deviation, s.d. 0.34) in TXA-treated patients
and by 0.41ml (s.d. 0.27ml) in the placebo group. Assuming a similar effect size is
present on the day 5 MRI scan using the sample size proposed for the main hypothesis
(n=280) we will be able to detect a group difference in the increase in relative PHO
with power of 0.89 and α=0.05 (independent samples t-test, 2-tailed). 
Statistical analyses
Group baseline characteristics will be compared between the TICH-2 MRI sub-study
and the main TICH-2 trial to examine the extent to which the TICH-2 MRI sub-study
participants are representative of the TICH-2 trial populations. To analyse the primary
hypothesis, presence of DWIHL post-SICH will be compared between treatment
groups using a binary logistic regression with adjustment for a selection of baseline
covariates; age, time from onset to randomisation, stroke severity (using National
Institutes of Health Stroke Scale), mean systolic blood pressure, known history of
antiplatelet treatment and baseline haematoma volume.
To test the secondary hypotheses, a group comparison test of PHO volume, PHO
diffusion metrics and day 90 combined haematoma cavity and surrounding FLAIR
hyperintensity volume between participants in the TXA and control treatment groups
will be performed. Other proposed analyses will include analyses of association
between presence of DWIHL and imaging markers of small vessel disease (CMB,
WMH) and likely diagnostic classification for CAA (based on CMB distribution and
presence of superficial siderosis); and exploratory analyses of associations between
imaging outcomes and clinical outcomes, with adjustment for haematoma expansion.
All regression analyses will be adjusted for the covariates listed previously.
Study organization and funding
The TICH-2 MRI sub-study is funded by a grant from British Heart Foundation (grant
number PG/14/96/31262). The TICH-2 trial is funded by a grant from the UK National
Institute for Health Research Health Technology Assessment programme (project
code 11_129_109). The TICH-2 trial (ISRCTN50867461) obtained ethical approval
from Nottingham-2 Research Ethics Committee on 19/11/12, and an amendment to
allow the TICH-2 MRI sub-study was approved on 21/04/2015 (amendment number
SA02/15). The University of Nottingham acts as the trial sponsor. The trial steering
committee for the TICH-2 trial oversees the TICH-2 MRI sub-study. Data monitoring
for the TICH-2 trial is performed by an independent data monitoring committee [3].
Recruitment into the MRI sub-study started in July 2015 and is due to end in
September 2017.
DISCUSSION
Tranexamic acid may have biological effects in the brain tissue that could alter the
outcome in SICH patients, independent to the postulated effects on haematoma
expansion. The main theoretical concern is that the haemostatic effects of TXA might
increase the risk of cerebral ischaemia. Understanding these effects is vital,
particularly if the results of ongoing trials [31] show an effect of TXA on outcome that
is not (or only partially) explained by an effect of TXA on haematoma expansion. This
study allows us to quantify treatment related brain changes (particularly prevalence of
ischaemic lesions, PHO volume and diffusion characteristics, and late post-SICH
tissue damage) in SICH patients in the context of a multicentre randomised controlled
trial. If the results of the ongoing trials support the use of TXA, then the opportunity to
study the potential therapeutic effects of TXA in acute cerebrovascular brain injury in
a controlled trial is unlikely to occur again. By including imaging markers of small
vessel disease and CAA in the analysis of DWIHL burden, we will be able to test
whether there is a subgroup of patients at risk of DWIHL following TXA treatment for
SICH, which will inform future studies of TXA in SICH and could ultimately influence
clinical practice. If the study shows a beneficial effect of TXA on PHO, then this study
may trigger studies of TXA in other acute brain pathologies associated with oedema
and inflammation.
A limitation of the recruitment process to the TICH-2 MRI sub-study is that recruitment
took place after-randomisation. As a result survivor bias could be a confounder as a
treatment allocation-related impact on survival of one group over the other could lead
to imbalance between the groups entering into the study. Recruitment to the MRI sub-
study pre-randomisation was discussed by the investigators during the study design
but was considered to be impractical due to the requirement for additional information
to be delivered to the participant / relatives and additional consent pre-randomisation
which could potentially lead to delays to randomisation for the main TICH-2 trial. To
identify a potential survivor bias we will compare group baseline characteristics
between the participants in the TICH-2 MRI sub-study and the main TICH-2 trial. To
attempt to control for possible imbalances we conduct the regression analyses
adjusting for pre-specified baseline variables, as detailed in the ‘statistical analyses’
section.
SUMMARY AND CONCLUSION
TXA is a widely available and inexpensive antifibrinolytic drug, which has the potential
of reducing neurotoxicity and neuroinflammation in SICH. However, it is also possible
that it may potentiate the risk of ischaemic events. The TICH-2 MRI sub-study will
assess the effectiveness of TXA in reducing inflammatory response, while also
determining whether there is an increased risk of ischaemic events following its
administration. This will inform future studies of TXA and, if found to be effective and
safe, have an important impact in clinical practice.
AUTHORS’ CONTRIBUTION
RAD, KF, PSM, IR, DW, RAS, TE, PMB and NS designed the study and were co-
applicants for funding. SP designed and will perform the image analyses. KF designed
and will perform the statistical analyses. RAD, SP, ZKL, KF and NS drafted the
manuscript. All authors reviewed and commented on the manuscript.
COMPETING INTERESTS
The authors have no conflicts of interest to disclose with respect to the research,
authorship and publication of this article.
ACKNOWLEDGEMENTS
This work was supported by the British Heart Foundation [grant number
PG/14/96/31262]
REFERENCES
1 McCormack PL. Tranexamic Acid: A review of its use in the treatment of
hyperfibrinolysis. Drugs 2012;72:585–617.
2 Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant
of mortality and poor outcome after intracerebral hemorrhage. Neurology
2006;66:1175–81.
3 Sprigg N, Robson K, Bath PM, et al. Intravenous tranexamic acid for hyperacute
primary intracerebral hemorrhage: Protocol for a randomized, placebo-
controlled trial. Int J stroke 2016;11:717–23.
4 Prabhakaran S, Gupta R, Ouyang B, et al. Acute brain infarcts after
spontaneous intracerebral hemorrhage: A diffusion-weighted imaging study.
Stroke 2010;41:89–94.
5 Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain
ischemia in intracerebral hemorrhage. Ann Neurol 2012;71:199–205.
6 Gregoire SM, Charidimou A, Gadapa N, et al. Acute ischaemic brain lesions in
intracerebral haemorrhage: Multicentre cross-sectional magnetic resonance
imaging study. Brain 2011;134:2376–86.
7 Kang DW, Han MK, Kim HJ, et al. New ischemic lesions coexisting with acute
intracerebral hemorrhage. Neurology 2012;79:848–55.
8 Garg RK, Liebling SM, Maas MB, et al. Blood pressure reduction, decreased
diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke
2012;43:67–71.
9 Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research
into small vessel disease and its contribution to ageing and neurodegeneration.
Lancet Neurol 2013;12:822–38.
10 Schreiber S, Bueche CZ, Garz C, et al. Blood brain barrier breakdown as the
starting point of cerebral small vessel disease? - New insights from a rat model.
Exp Transl Stroke Med 2013;5:4.
11 Baharoglu MI, Germans MR, Rinkel GJE, et al. Antifibrinolytic therapy for
aneurysmal subarachnoid haemorrhage. Cochrane database Syst Rev 2013.
12 Ross J, Al-Shahi Salman R. The frequency of thrombotic events among adults
given antifibrinolytic drugs for spontaneous bleeding: Systematic review and
meta-analysis of observational studies and randomized trials. Curr Drug Saf
2012;7:44–54.
13 Perel P, Al-Shahi Salman R, Kawahara T, et al. CRASH-2 (Clinical
Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial
bleeding study: the effect of tranexamic acid in traumatic brain injury--a nested
randomised, placebo-controlled trial. Health Technol Assess 2012;16.
14 CRASH-2 Collaborators. Effect of tranexamic acid in traumatic brain injury: a
nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding
Study). BMJ 2011;343:d3795.
15 Roberts I, Shakur H, Ker K, et al. Antifibrinolytic drugs for acute traumatic injury.
Cochrane database Syst Rev 2011;12:CD004896.
16 Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and
inflammation: Role for plasminogen activators and matrix metalloproteinases. J
Neurosci Res 2002;69:1–9.
17 Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by
plasmin-catalyzed degradation of laminin. Cell 1997;91:917–25.
18 Endo A, Nagai N, Urano T, et al. Proteolysis of neuronal cell adhesion molecule
by the tissue plasminogen activator-plasmin system after kainate injection in the
mouse hippocampus. Neurosci Res 1999;33:1–8.
19 Later AFL, Sitniakowsky LS, van Hilten JA, et al. Antifibrinolytics attenuate
inflammatory gene expression after cardiac surgery. J Thorac Cardiovasc Surg
2013;145:1611–1616.e4.
20 Leira R, Dávalos A, Silva Y, et al. Early neurologic deterioration in intracerebral
hemorrhage: Predictors and associated factors. Neurology 2004;63:461–7.
21 Fu Y, Hao J, Zhang N, et al. Fingolimod for the treatment of intracerebral
hemorrhage: A 2-arm proof-of-concept study. JAMA Neurol 2014;71:1–10.
22 Li N, Liu Y., Ma L, et al. Association of molecular markers with perihematomal
edema and clinical outcome in intracerebral hemorrhage. Stroke 2013;44:658–
63.
23 Venkatasubramanian C, Mlynash M, Finley-Caulfield A, et al. Natural history of
perihematomal edema following intracerebral hemorrhage measured by serial
magnetic resonance imaging. Stroke 2011;42:73–80.
24 Butcher KS, Baird T, MacGregor L, et al. Perihematomal edema in primary
intracerebral hemorrhage is plasma derived. Stroke 2004;35:1879–85.
25 Carhuapoma JR, Barker PB, Hanley DF, et al. Human brain hemorrhage:
Quantification of perihematoma edema by use of diffusion-weighted MR imaging.
Am J Neuroradiol 2002;23:1322–6.
26 Kidwell CS, Saver JL, Mattiello J, et al. Diffusion-perfusion MR evaluation of
perihematomal injury in hyperacute intracerebral hemorrhage. Neurology
2001;57:1611–7.
27 Pszczolkowski S, Gallagher RG, Law ZK, et al. Automatic Quantification of
Haematoma and Surrounding Oedema in MRI of Acute Spontaneous
Intracerebral Haemorrhage: Preliminary Results for the TICH-2 MRI Sub-study.
In: Proc. ISMRM. 2017.
28 Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related
white matter changes applicable to MRI and CT. Stroke 2001;6:1318–23.
29 Gregoire SM, Chaudhary UJ, Brown MM, et al. The Microbleed Anatomical
Rating Scale (MARS): Reliability of a tool to map brain microbleeds. Neurology
2009;73:1759–66.
30 Sprigg N, Renton CJ, Dineen RA, et al. Tranexamic acid for spontaneous
intracerebral hemorrhage: A randomized controlled pilot trial
(ISRCTN50867461). J Stroke Cerebrovasc Dis 2014;23:1312–8.
31 Law ZK, Meretoja A, Engelter ST, et al. Treatment of intracerebral haemorrhage
with tranexamic acid - A review of current evidence and ongoing trials. Eur
Stroke J 2017;2:13–22.
Figure 1 – TICH-2 MRI substudy flowchart. Details of participant flow for the TICH-2
trial, including the schedule for randomisation, treatment, cranial CT, clinical
assessments and non-MRI follow-up assessments have been described in Sprigg et
al [3].
Figure 2 – Summary of image processing and outputs in the TICH-2 MRI substudy.
Figure 3 - Measurement of perihaematomal oedema (PHO) volume and apparent
diffusion coefficient (ADC). (a) Axial FLAIR image in native T1 space showing the PHO
delineation from which the PHO volume can be derived. (b) ADC map in native T1
space. PHO ADC values are calculated from the voxels within the PHO delineation in
the ADC map.
